Notably, in our analysis with cBioPortal for cancer genomics (http://www.cbioportal.org/), genetic alterations in both NRF2 and c-MET were found in 39 (13%) of 311 patients with ovarian carcinoma and the co-occurrence was statistically significant (p = 0.03), which further supports the association of NRF2 with c-MET oncogene. This evidence concerns the gene MET and cancer.